Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
IL-6 receptor blockade significantly reduces relapse rates in MOG antibody-associated disease, showing comparable efficacy to high-dose IVIG with a favorable safety profile, supporting its role in relapse prevention.
A novel adaptive Sino-Nasal Outcome Test (SNOT) yields improved correlation with computed tomography findings in chronic rhinosinusitis, enhancing clinical assessment and differentiation from allergic rhinitis.
Two immunologically distinct, age-independent subtypes of new-onset type 1 diabetes demonstrate differing progression rates and therapeutic responses, offering a path toward tailored immunotherapies.
This article reviews a retrospective study evaluating the feasibility and outcomes of a 24-week abrocitinib tapering regimen in moderate-to-severe atopic dermatitis, comparing dose reduction versus interval extension approaches and their im
This study evaluates the successful 24-week tapering of abrocitinib in moderate-to-severe atopic dermatitis patients, comparing dose reduction versus interval extension tapering regimens and demonstrating high feasibility with substantial d
EBV-positive diffuse large B-cell lymphoma exhibits severe systemic antiviral T-cell impairments and a suppressive tumor microenvironment driven by LMP1, revealing novel immunobiological insights with therapeutic implications.
Severe allergic transfusion reactions in group O recipients receiving group B or AB plasma or platelets are linked to IgE antibodies against the α-Gal epitope, highlighting a novel immunological mechanism and potential risk stratification a
A 2026 European Heart Journal study identifies macrophage circHIPK2 as a regulator of post-MI inflammation and fibrosis, with macrophage-targeted silencing improving cardiac remodeling in mice and showing translational promise in human myoc
Single-cell and spatial transcriptomics suggest that cardiac sarcoidosis evolves through region-specific inflammatory programs and intracardiac B-cell autoimmunity, with periplakin emerging as a candidate autoantigen.
New data identify GPR15L as an epithelial host-defense peptide that reshapes the colonic microbiota, reduces experimental colitis, and may have therapeutic relevance in inflammatory bowel disease.
In the phase 3A NIMBLE trial, switching biologic-responsive severe asthma patients to twice-yearly depemokimab preserved overall control and showed comparable safety, but formal noninferiority versus continued mepolizumab or benralizumab fo
This study used immune-cell gene expression and genetic analyses to identify causal genes and immune pathways linked to type 2 diabetes and its complications, highlighting diabetic neuropathy as a distinct cluster and prioritising ten promi
In a phase 2 randomized trial, oral vemircopan did not improve clinical outcomes over placebo in AChR-antibody–positive generalized myasthenia gravis, despite a mechanistically attractive strategy to selectively inhibit the alternative comp
Long-term data from the ULTIMATE open-label extension study demonstrates sustained efficacy and safety of ublituximab in relapsing multiple sclerosis over five years, with significant reductions in relapse rates and disability progression c
A large-scale quality improvement study reveals that reclassifying penicillin allergies and providing pharmacy support can increase the use of intracameral cefuroxime from 2% to over 70%, significantly improving evidence-based prophylaxis i
A pilot randomized controlled trial and translational study demonstrate that Sopoongsan (SPS) effectively reduces chronic upper body pruritus in atopic and seborrheic dermatitis by inhibiting STAT1-mediated inflammatory pathways, offering a
A Phase IIb clinical trial demonstrates that pumecitinib 3% gel significantly improves skin clearance in adults with mild-to-moderate atopic dermatitis. Twice-daily application proved superior to once-daily dosing, maintaining a favorable s
The SHINE trial, despite missing its primary endpoint due to a high placebo response, suggests that high-dose vilobelimab significantly reduces draining tunnels in moderate-to-severe hidradenitis suppurativa, offering a potential new therap
A phase 1/2 study reveals that a single dose of aletekitug, an anti-IL-18 antibody, provides durable clinical improvement and broad molecular modulation in moderate-to-severe atopic dermatitis, targeting pathways beyond traditional Type 2 i
A randomized trial (NCT05969730) shows that baricitinib plus topical corticosteroids significantly outperformed azathioprine in achieving EASI 75 at 12 weeks (65% vs. 15%) in patients with moderate-to-severe atopic dermatitis, with both tre
Open language-specific specialty feeds and department pages.